CoChat

The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres

Bonastre, Julia, Le Pen, Claude, Soubrane, Gis??le, Quentel, Gabriel · 2003 · PharmacoEconomics

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Abstract

Objective To describe the economic impact of age-related macular degeneration (AMD) and to assess its medical and non-medical costs.Design and settings An observational study was carried out in 105 patients in two French centres in a sample of 105 French patients. All consecutive patients, consulting during a 3-week period, were included provided they were 60 years of age or older and they presented an exudative form of AMD with a distant visual acuity in the best eye < or = 20/40. Data collected included clinical items, treatment modalities, medical follow-up, transport costs, impact of AMD on living conditions and welfare payments related to visual impairment. Costs were presented in 2000 values.Perspective General payer perspective (Social Security, private health insurance and patient).Results Mean age was 79.3 years and ranged from 62.8-95 years. Average length of disease evolution was 3.5 years. During a 3-month period, patients had a mean of 2.6 visits to the ophthalmologist. Thirty percent of the patients used vascular medications and 72.4% had been previously treated by laser photocoagulation. Only 10% had benefited from visual rehabilitation. Annual AMD cost per patient was 3660.29 euros (EUR) [95% CI: 2881.92-4438.62]. Half of these annual costs were medical costs. Other major cost components were home help costs EUR904.91 [95% CI: 478.88-1330.94] and transport costs for care EUR542.73 [95% CI: 146.31-939.14]. Non-medical costs were significantly higher for patients with more severe disease.Conclusions The economic argument that costs are higher in patients with the lowest visual acuity emphasises the necessity of early detection and treatment of patients with AMD.

Overview

Integrity signals

Registry

Crossref · 10.2165/00019053-200321030-00003

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 3

  1. Arnold, 1999, Clin Evid, 2, 247
  2. Gibson, 1985, Trans Ophthalmol Soc UK, 104, 196
  3. Wu, 1987, Jpn J Ophthalmol, 31, 349

Cited by

See all 70

Metadata

Authors
Bonastre, J., Le Pen, C., Soubrane, G., & Quentel, G.
Affiliations
  • Hôpital Intercommunal de Créteil (FR)
  • Centre Ophtalmologique d'Imagerie et de Laser (FR)
Venue
PharmacoEconomics
Published
2003
Volume
21
Issue
3
Pages
181-190
ISSN
1170-7690 (ISSN-L)
OpenAlex
W1996994847
Cited by
65
References
41
Citations by year
2025: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 1
FWCI
9.61
Type
journal article
Language
en
Open access
closed
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novartis Pharma
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
Keywords
age-related macular degeneration, exudative AMD, economic burden, health care costs, non-medical costs, transportation costs, visual impairment, welfare benefits, visual rehabilitation, laser photocoagulation, vascular therapy, visual acuity, early detection
MeSH terms
Aged, Aged, 80 and over, Audiovisual Aids, France, Humans, Macular Degeneration, Middle Aged, Visual Acuity, Cohort Studies, Cost of Illness

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres. https://app.cochat.ai/papers/10.2165/00019053-200321030-00003
The paper
Bonastre, J., Le Pen, C., Soubrane, G., & Quentel, G. (2003). The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres. PharmacoEconomics. https://doi.org/10.2165/00019053-200321030-00003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.